Evidence Hub

A multifaceted clinical portrait of Ebstein’s anomaly: a case series

P. Vlachakis, E. Nyktari, G. Oikonomou, A. Apostolos, S. Sideris, Konstantinos Toutouzas, C. Tsioufis, Maria Drakopoulou

European Heart Journal: Case Reports, 2025

Abstract

Abstract Background It was in 1866 when Wilhelm Ebstein first described a rare case of a 19-year-old cyanotic patient with tricuspid valve regurgitation caused by a congenital malformation. Since then, Ebstein’s anomaly (EA) has been recognized as a condition that exhibits a diverse clinical course with a formidable challenge for clinicians in terms of diagnosis, management, and prognosis. Case summary We present a case series of four patients with EA, shedding light on the varied clinical manifestations, treatment approaches, and outcomes that underscore the multifaceted nature of this condition. Discussion The management of EA requires a comprehensive and individualized approach in specialized centres. The cardiologists responsible for the long-term care of these patients are faced with various challenging ‘dilemmas’ in the clinical course of the disease at different stages. The evolving landscape of cardiology offers a promising avenue for improving the outcomes and quality of life of patients with EA.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free